What Obesity Care Programs Need to Know About WHO’s New GLP-1 Guidelines

Articles

Last edit: February 23, 2026

December 15, 2025

Emma Lugten

The World Health Organization recently released its first global guideline on the use of GLP-1–based therapies for obesity, a milestone that signals a major shift in how health systems worldwide should approach long-term obesity care.

For obesity programs, digital-health organizations, and chronic-care providers, the message is clear: GLP-1s can be valuable tools, but only when embedded within a structured framework of behavioral support, lifestyle intervention, and ongoing monitoring.

Here’s a guide to what programs need to understand and how to prepare.

1. WHO Defines Obesity as a Chronic, Relapsing Disease, Not a Short-Term Problem or Fix

The guideline reinforces a position many clinicians already share: obesity requires ongoing management similar to other chronic diseases. This means obesity programs must prioritize continuity, long-term engagement, and structured monitoring, not episodic care. Many times patients see weight loss as a goal that they reach and that concludes their obesity care journey. The WHO emphasizes the ongoing nature of obesity as a disease, and obesity care as a necessity.

2. GLP-1s Are Recommended Conditionally and Only as Part of Comprehensive Care

WHO does not recommend medication alone. The guideline emphasizes:GLP-1 therapies should be considered as one component of a broader care plan.

Treatment decisions should reflect patient context, preferences, and access. Programs must integrate behavioral interventions and lifestyle support alongside medication. For organizations delivering obesity care, this signals a need to strengthen or formalize their behavioral-support models, including: coaching, education, medical nutrition therapy (MNT), activity support, and digital engagement.

3. Behavioral Support Is Essential-Not Optional

The guideline places intensive behavioral therapy (IBT) at the center of obesity care. Programs should ensure they can offer:

Structured lifestyle guidance
Goal setting and personalized plans
Coaching or counseling pathways
Tools for sustained behavior change
Ongoing check-ins and accountability
Medical nutrition therapy (MNT) when needed

This isn’t merely additive, it is foundational to responsible GLP-1 prescribing and to long-term patient outcomes.

4. Monitoring Frameworks Must Become Core Infrastructure

One of the most operationally important implications for obesity programs is WHO’s emphasis on continuous monitoring and follow-up. Because obesity is chronic and GLP-1 outcomes evolve over time, programs need systems that can:

Track weight, body composition, and metabolic markers
Detect early signs of weight regain or treatment non-response
Support long-term engagement after dose changes or discontinuation
Ensure care teams can intervene proactively and remain the decision makers

This is where digital health infrastructure becomes essential. Connected devices, remote monitoring, and automated data flows make it possible to support thousands of patients consistently without adding extensive labor burden to clinical teams.

5. What Obesity Programs Should Do Next

To align with WHO’s guidance and strengthen patient outcomes, programs can begin by:

Evaluating their behavioral-support offering – ensuring it is structured, consistent, and accessible.
Implementing device-based monitoring- enabling ongoing, objective tracking of patient progress without the barriers of in-office care.
Ensuring continuity models beyond initial weight loss – including maintenance and relapse-prevention.
Building customizable data workflows that let care teams intervene early, efficiently, and at scale, while keeping the decision-making in the hands of the clinician.
Partnering with technology providers already equipped to deliver these components reliably.

The Bottom Line for Obesity Programs

The new WHO guideline is not simply a statement on medications. It is a blueprint for comprehensive, long-term obesity care. Programs that combine medication, behavioral support, and robust monitoring will be best positioned to deliver durable outcomes, meet patient expectations, reduce clinical burden, and scale responsibly.

Withings Health Solutions stands ready to support that evolution with the technology, partnerships, and evidence-aligned frameworks that make multimodal obesity care possible.